Hybridoma technology involves the production of monoclonal antibodies specific to an antigen of interest. The somatic fusion of B lymphocytes of the spleen with immortal myeloma cells gives rise to a hybridoma cell line that can be perpetually propagated to produce clonally identical antibodies, as these hybridoma cells inherit the indefinite growth properties of myeloma cells and the antibody secretion capabilities of B-lymphocytes. Monoclonal antibodies produced by a unique hybridoma cell line are homogeneous and recognize a single epitope of an antigen.
Monoclonal antibodies produced from hybridoma technology are used in the following applications:
Selection of the optimal immortal cell line is critical for achieving the desired attributes of the hybridoma. Lack of suitable fusion partners hampers the applicability of monoclonal antibodies in research and immunotherapy. For example, the application of xenogeneic monoclonal antibodies in therapy and in vivo diagnostics often results in an undesirable human anti-mouse antibody (HAMA) response.
Our selection of fusion partner cell lines include serum- and animal component-free propagation options. Choose from dozens of options to find the optimal fusion partner for your application and increase the efficiency of hybridoma growth and antibody synthesis.